Lexeo Therapeutics
Market cap $236M 82.8M shares (10-Q, Nov 12, 2026) × $2.85 close Nov 17, 2026
Most recent annual filing: 2026-03-30
- LX3010 / LX3030 LX3050 LX3070Early 2027LX3010 / LX3030 LX3050 LX3070, Early 2027, notable
- Next FA development candidate IND2027Next FA development candidate IND, 2027, notable
- LX2006 FA pivotal topline2H 2027LX2006 FA pivotal topline, 2H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
LX2020
LX2021
LX2022
LX1001
LX1021
LX1020
LX1004
LX3010
MTL-104LX3030
MTL-707LX3050
MTL-501LX3070
MTL-801Technology platforms
Sf9-baculovirus AAV manufacturing platform
Optimized Sf9 baculovirus suspension-based AAV manufacturing process offering improved scalability and reduced cost while maintaining purity and potency, supporting cardiac genetic medicine programs.
Sf9 baculovirus manufacturing platform
Optimized Sf9 baculovirus AAV manufacturing platform designed for high yield, improved genomic purity, reduced empty capsids, and commercial-scale gene therapy production; supports Lexeo's cardiac and neurological gene therapy pipeline including LX2006 and LX2020.
Capital (as filed)
- Cash
- $90.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $105M Sep 30, 2026
- Long-term investments
- $24.4M Sep 30, 2026
- Operating cash flow
- −$28.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $219M cash, runway into 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-10-29 S-3 · Shelf registration
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-17 UPDATE: Lexeo Therapeutics (LXEO) - The Call Option Got Exercised 🔒 Paid
- 2026-09-23 UPDATE: Lexeo Therapeutics (LXEO) - The $8.3 Million Pipeline and the Market’s Shrug 🔒 Paid
- 2026-08-13 UPDATE: Lexeo Therapeutics (LXEO) - The Quiet ATM 🔒 Paid
- 2026-08-06 UPDATE: Lexeo Therapeutics (LXEO) - The FDA Just Graded the Data the Market Failed 🔒 Paid
- 2026-06-15 UPDATE: Lexeo Therapeutics (LXEO) - The Pivotal Protocol Lands, and the FDA Just Dropped the Hardest Endpoint 🔒 Paid
- 2026-01-12 UPDATE: Lexeo (LXEO) Drops 25%+ on “Positive” Data – Why Did the Market Halt on the LX2020 Readout? 🔒 Paid
- 2025-12-22 Lexeo Therapeutics (LXEO): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Lexeo Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-22 Watch Lexeo Therapeutics (LXEO): Scientific Due Diligence for Lead and Pipeline Products Regulatory tailwinds (FDA acceptance of manufacturing switch and surrogate endpoint) and 3-year cash runway offer favorable risk/reward, but the author is waiting for the LX2020 safety dataset and pivotal protocol before committing capital.
- 2026-01-12 Buy speculative UPDATE: Lexeo (LXEO) Drops 25%+ on "Positive" Data – Why Did the Market Halt on the LX2020 Readout? Market overreacted to ambiguous efficacy language while ignoring definitive protein expression; the scientific thesis remains intact and the J&J collaboration provides a Plan B.
- 2026-06-15 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Pivotal Protocol Lands, and the FDA Just Dropped the Hardest Endpoint Three of four binary regulatory questions closed favorably (frataxin co-primary dropped, randomized design accepted, Sf9 commercial process cleared), and the pivotal trial is statistically powered against an effect size the drug has already exceeded in Phase I/II.
- 2026-08-06 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The FDA Just Graded the Data the Market Failed RMAT designation confirms the FDA read the January interim LX2020 data as preliminary evidence of clinical benefit, giving LX2020 a plausible accelerated-approval path that didn't visibly exist before, while LX2006 remains the value driver.
- 2026-08-13 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Quiet ATM Operational execution matched the plan (first patient dosed, RMAT collected, G&A cut), but the ATM sold ~10% of the float at depressed prices, making the thesis slightly more expensive per share while leaving the core thesis intact.
- 2026-09-23 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The $8.3 Million Pipeline and the Market's Shrug The Mantle acquisition costs roughly six weeks of burn and adds CNS FA optionality without touching runway or SUNRISE-FA 2 priority, but the 'focused cardiovascular specialist' framing no longer holds and the ATM overhang persists.
- 2026-11-17 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Call Option Got Exercised 12-month high-dose HEROIC-PKP2 data show an 80% NSVT reduction running opposite to natural history, with FDA openness to NSVT as a pivotal surrogate, upgrading LX2020 from a call option to a second real pivotal asset alongside LX2006.
- Long call · opened Jan 12, 2026 at $8.12 · -64.8% vs XBI +17.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“In August 2026, Lexeo received Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 from the FDA based on recent interim data from its ongoing Phase I/II clinical trial in PKP2-ACM.”
matched to LX2006 (SUNRISE-FA 2 pivotal) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (31)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-Kcompany site may be offline after the acquisition; linked to the SEC copy · original
- Nov 16, 20268-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1→ BD updateToday's HEROIC-PKP2 interim data delivered what January's readout couldn't: an 80% mean NSVT reduction in high-dose patients that deepens over time, 100% below the clinically meaningful arrhythmia threshold at latest assessment, and FDA confirmation that NSVT can serve as the primary surrogate endpoint for accelerated approval — giving LX2020 a pivotal path and a 2H 2027 start date.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 15, 2026ReleaseLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026→ BD updateSummary on the 8-K of Nov 16, 2026company site may be offline after the acquisition
- Nov 2, 2026ReleaseLexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in Novembercompany site may be offline after the acquisition
- Oct 29, 2026S-3Shelf registration
- Oct 19, 2026ReleaseLexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMcompany site may be offline after the acquisition
- Oct 8, 2026ReleaseLexeo Therapeutics to Participate in the Chardan Healthcare Conferencecompany site may be offline after the acquisition
- Oct 1, 2026ReleaseLexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)company site may be offline after the acquisition
- Sep 29, 20268-KCurrent report: acquisition / disposition, unregistered sale of equity
- Sep 23, 2026ReleaseLexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forumcompany site may be offline after the acquisition
- Sep 22, 2026ReleaseLexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia→ BD updateSummary on the 8-Kcompany site may be offline after the acquisition; linked to the SEC copy · original
- Sep 22, 20268-KCurrent report: material agreement, other events · EX-99.1→ BD updateLexeo just transformed from a focused cardiac gene therapy company into a multimodal Friedreich ataxia platform — acquiring four frataxin programs (including one in the clinic) for just $8.3M upfront, while launching three CNS gene therapy collaborations, all without touching the 2028 cash runway guidance.BD extracted 5 program updates from this document → LXEO pipeline
- Sep 2, 2026ReleaseLexeo Therapeutics to Participate in Upcoming Investor Conferences in Septembercompany site may be offline after the acquisition
- Aug 12, 2026ReleaseLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsBD extracted 2 program updates from this document → LXEO pipelinecompany site may be offline after the acquisition; linked to the SEC copy · original
- Aug 12, 20268-KCurrent report: results of operations, other events · EX-99.1
- Aug 12, 202610-QQuarterly report
- Aug 5, 2026ReleaseLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathycompany site may be offline after the acquisition
- Jun 29, 20268-KCurrent report: shareholder vote
- Jun 17, 2026ReleaseLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxiacompany site may be offline after the acquisition
- Jun 15, 2026ReleaseLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxiacompany site may be offline after the acquisition; linked to the SEC copy · original
- Jun 15, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 19, 2026ReleaseLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conferencecompany site may be offline after the acquisition
- May 11, 2026ReleaseLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlightscompany site may be offline after the acquisition; linked to the SEC copy · original
- May 11, 20268-KCurrent report: results of operations, other events · EX-99.1
- May 11, 202610-QQuarterly report
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Apr 30, 20268-KCurrent report: officer / director change
- Mar 30, 20268-KCurrent report: results of operations, other events · EX-99.1
- Mar 30, 202610-KAnnual report
20 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 4, 2026EFFECTRegistration effective
- Oct 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 30, 2026ARSAnnual report to shareholders
- Apr 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 30, 2026S-8Employee plan registration
- Mar 27, 2026SCHEDULE 13G/A13G amendment